Impact of Adiposity Measures on Heart Disease Risk Alike

Article

Body mass index (BMI), waist circumference, and waist-to-hip ratio all have a similar strength of association with cardiovascular disease, but do not significantly improve risk prediction when information on blood pressure, diabetes, and lipid levels is available, according to a study published online March 11 in The Lancet.

FRIDAY, March 11 (HealthDay News) -- Body mass index (BMI), waist circumference, and waist-to-hip ratio all have a similar strength of association with cardiovascular disease, but do not significantly improve risk prediction when information on blood pressure, diabetes, and lipid levels is available, according to a study published online March 11 in The Lancet.

David Wormser, of the University of Cambridge in the United Kingdom, and colleagues from the Emerging Risk Factors Collaboration, a consortium of 200 scientists from 17 countries, investigated the association of adiposity measures (BMI, waist circumference, and waist-to-hip ratio) with the risk of first-onset cardiovascular disease. Individual records from 58 cohorts, totaling 221,934 people, were studied to calculate hazard ratios (HRs) per one standard deviation increase in adiposity values.

The researchers found that, in people with BMI 20 kg/m² or higher, the risk of a cardiovascular event was increased (HRs, 1.23 with BMI, 1.27 with waist circumference, and 1.25 with waist-to-hip ratio) after adjusting for age, gender, and smoking status. After adjustment for risk factors, including systolic blood pressure, history of diabetes, and lipid levels, HRs were 1.07 with BMI, 1.10 with waist circumference, and 1.12 with waist-to-hip ratio. Adding information about these three measures in a risk prediction model using conventional cardiovascular disease risk factors had minimal impact on its accuracy.

"BMI, waist circumference, and waist-to-hip ratio, whether assessed singly or in combination, do not importantly improve cardiovascular disease risk prediction in people in developed countries when additional information is available for systolic blood pressure, history of diabetes, and lipids," the authors write.

Several authors disclosed financial ties with the pharmaceutical industry.

Related Content

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.